Table 3.

List of nanomedicine approved by FDA or presently in clinical trial for diagnosis or therapy of CVRDs.

Drug/Nanocarrier	Clinical Trial Types	Purpose	Indications	Benefits	Ref.
USPIONPs	N/A	Diagnostic	Atherosclerotic plaque	Noninvasive method of imaging carotid atheroma.	[132,133,134]
USPIONPs	N/A	Diagnostic	Acute myocardial infarction	Noninvasive method of imaging inflammatory myocytes.	[135]
Prednisolone phosphate/liposomes	Randomized, placebo-controlled study	Therapeutic	Inflammatory atherosclerosis	Benefiting image assisted technology	[136]
Silica-AuNPs	Multi-center, observational, open-label, three arms study	Therapeutic	Atherosclerosis	Application of novel invasive Plasmonic photothermal therapy using near-infrared laser irradiation.	[137]
LABR-312/Liposomes	Prospective, randomized, multicenter, double-blind, placebo-controlled trial	Therapeutic	Atherosclerosis	Much more effective in subjects with proinflammatory state, such as diabetes mellitus and high baseline monocyte count.	[138]
TriCor/Nanocrystals	FDA approved	Therapeutic	Hyperlipidemia	Tablets for oral use is available.	[161]

USPIONPs: Ultrasmall super paramagnetic iron oxide nanoparticles; AuNPs: Gold Nanoparticles.